Loading clinical trials...
Loading clinical trials...
The strategy of intermittent triple therapy for people living with HIV was validated in France following the randomized clinical trial QUATUOR. There is little data in real life, as shown in the meta-analysis of Parienti JJ et al. Currently this strategy is proposed by some teams in France, but is not recommended internationally. The research hypothesis is that intermittent treatment is an effective and safe option in a therapeutic lightening strategy in people living with HIV People living with HIV adults followed in Strasbourg who have benefited from intermittent treatment The expected results will consist of an improvement in knowledge on the efficacy and tolerance of this therapeutic strategy.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Service Le Trait d'Union - CHU de Strasbourg - France
Strasbourg, France
Start Date
February 21, 2024
Primary Completion Date
February 1, 2025
Completion Date
February 21, 2025
Last Updated
August 29, 2024
200
ESTIMATED participants
Lead Sponsor
University Hospital, Strasbourg, France
NCT06694805
NCT04142047
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07428330